<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008354</url>
  </required_header>
  <id_info>
    <org_study_id>5238</org_study_id>
    <nct_id>NCT05008354</nct_id>
  </id_info>
  <brief_title>Effect of Pyridoxine on Behavioral Adverse Events of Levetiracetam</brief_title>
  <acronym>EPYLEB</acronym>
  <official_title>Investigation of Pyridoxine Effect on Behavioral Adverse Events of Levetiracetam in Adult Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nasim Tabrizi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mazandaran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mazandaran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a two-arm parallel group randomized double-blind placebo-controlled trial with&#xD;
      the aim of Investigating pyridoxine effect on behavioral side effects of levetiracetam in&#xD;
      adult patients with epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral side effects</measure>
    <time_frame>3 weeks</time_frame>
    <description>Behavioral side effects are measured by SCL-90-R questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Epilepsy</condition>
  <condition>Pyridoxine</condition>
  <condition>Behavior Problem</condition>
  <arm_group>
    <arm_group_label>Pyridoxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>Pyridoxine tablet 40mg once daily</description>
    <arm_group_label>Pyridoxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ageâ‰¥18 years&#xD;
&#xD;
          -  Patients with epilepsy&#xD;
&#xD;
          -  Patients who are treated by levetiracetam (Levebel, Cobel darou) in recent month&#xD;
&#xD;
          -  Complaint of behavioral problem&#xD;
&#xD;
          -  Patient's consent for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of known psychiatric disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Incidence of psychotic side effects including hallucination, psychosis, suicidal idea&#xD;
             or attempt&#xD;
&#xD;
          -  Treatment with psychiatric medications&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Mental retardation to the degree that intervenes comprehension and response to&#xD;
             questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nasim Tabrizi, MD</last_name>
    <phone>+981133343015</phone>
    <email>nasimtabrizi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bu Ali Sina Hospital</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <zip>4815837477</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faezeh Asghari, MD</last_name>
      <phone>+981133343016</phone>
      <email>faeze.asghari.1995@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nasim Tabrizi, MD</last_name>
      <phone>+981133343015</phone>
      <email>nasimtabrizi@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mazandaran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Nasim Tabrizi</investigator_full_name>
    <investigator_title>Associate professor of neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

